Bicocca Open Archive

Logo unimib boa
FALANGA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.461
AS - Asia 6.331
EU - Europa 3.860
SA - Sud America 1.178
AF - Africa 190
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 21.033
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.179
SG - Singapore 2.727
HK - Hong Kong 1.363
RU - Federazione Russa 1.002
BR - Brasile 895
CN - Cina 793
VN - Vietnam 648
IE - Irlanda 557
IT - Italia 554
SE - Svezia 527
DE - Germania 472
FR - Francia 205
CA - Canada 187
IN - India 170
GB - Regno Unito 139
BD - Bangladesh 108
AR - Argentina 102
AT - Austria 85
UA - Ucraina 79
ID - Indonesia 76
IQ - Iraq 67
MX - Messico 66
ZA - Sudafrica 59
TR - Turchia 51
FI - Finlandia 45
NL - Olanda 44
EC - Ecuador 42
PH - Filippine 42
PK - Pakistan 42
JP - Giappone 39
ES - Italia 37
SA - Arabia Saudita 34
CO - Colombia 32
KR - Corea 31
MA - Marocco 29
VE - Venezuela 27
PL - Polonia 24
UZ - Uzbekistan 22
CL - Cile 20
PE - Perù 19
PY - Paraguay 19
RO - Romania 19
TN - Tunisia 17
ET - Etiopia 16
DK - Danimarca 12
DZ - Algeria 12
KE - Kenya 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
JO - Giordania 11
MY - Malesia 11
NP - Nepal 11
EG - Egitto 10
IL - Israele 10
BO - Bolivia 9
CH - Svizzera 9
OM - Oman 9
AU - Australia 8
KZ - Kazakistan 8
AL - Albania 7
CZ - Repubblica Ceca 7
GR - Grecia 7
LB - Libano 7
MU - Mauritius 7
PA - Panama 7
DO - Repubblica Dominicana 6
PT - Portogallo 6
TH - Thailandia 6
CR - Costa Rica 5
KG - Kirghizistan 5
KH - Cambogia 5
PS - Palestinian Territory 5
GE - Georgia 4
IR - Iran 4
JM - Giamaica 4
SN - Senegal 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
GA - Gabon 3
HN - Honduras 3
LY - Libia 3
RS - Serbia 3
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BE - Belgio 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
EE - Estonia 2
HU - Ungheria 2
LT - Lituania 2
ML - Mali 2
MM - Myanmar 2
NE - Niger 2
NZ - Nuova Zelanda 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BF - Burkina Faso 1
Totale 21.014
Salva come PNG Salva come JPEG
Città #
Singapore 1.394
Hong Kong 1.347
Ann Arbor 981
Fairfield 850
Ashburn 706
Dublin 553
San Jose 485
Woodbridge 417
Wilmington 375
Houston 363
Chandler 362
Frankfurt am Main 333
New York 326
Princeton 310
Dallas 306
Cambridge 286
Seattle 262
Chicago 253
The Dalles 213
Ho Chi Minh City 206
Santa Clara 206
Hanoi 167
Beijing 162
Altamura 140
Jacksonville 140
Lawrence 140
Lauterbourg 136
Los Angeles 134
Milan 120
Moscow 86
São Paulo 83
Ottawa 81
San Diego 80
Council Bluffs 60
Buffalo 51
Nuremberg 51
Toronto 51
Vienna 48
Andover 46
Jakarta 40
Shanghai 38
London 35
Falls Church 32
Helsinki 32
Orem 32
Hefei 31
Tokyo 31
Rio de Janeiro 29
Baghdad 28
Salt Lake City 28
Seoul 28
Guangzhou 24
Nanjing 24
Redmond 24
Dearborn 22
Da Nang 21
Tashkent 21
Brasília 20
Dong Ket 20
Johannesburg 19
New Delhi 19
Phoenix 19
Warsaw 19
Dhaka 18
Haiphong 18
Norwalk 18
Florence 16
Montreal 16
Atlanta 15
Brooklyn 15
Cape Town 15
Chennai 15
Tampa 15
Ankara 14
Belo Horizonte 14
Campinas 14
Hải Dương 14
Lahore 14
Addis Ababa 13
Boardman 13
Elk Grove Village 13
Istanbul 13
Medellín 13
Paris 13
Poplar 13
Quito 13
Rome 13
Amsterdam 12
Columbus 12
Curitiba 12
Delhi 12
Guayaquil 12
Jinan 12
Lima 12
Wuhan 12
Chengdu 11
Denver 11
Hangzhou 11
Jeddah 11
Porto Alegre 11
Totale 13.445
Salva come PNG Salva come JPEG
Nome #
A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit β3 impact breast cancer cell extravasation 317
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 307
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 272
Treatment of venous thromboembolism with tinzaparin in oncological patients 270
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study 257
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 256
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer 250
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 238
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 233
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study 231
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 227
Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation 221
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 206
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 205
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 200
ISTH interim guidance on recognition and management of coagulopathy in COVID-19 199
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 195
Thrombin generation predicts early recurrence in breast cancer patients 195
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 192
Clozapine-induced anemia: A case-report 183
Hemostatic biomarkers in occult cancer and cancer risk prediction 183
Proceedings of the Second “International Conference on Thrombosis and Hemostasis Issues in Cancer”. September 19-21, 2003. Bergamo, Italy 180
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary 176
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment 176
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 176
DOACs and “newer” hemophilia therapies in COVID-19: Reply 175
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 174
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 172
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 171
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 170
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE 167
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 166
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update 165
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 165
Laboratory haemostasis monitoring in COVID-19 164
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review 164
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 163
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 161
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 161
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery 160
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 158
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine 157
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera 156
THE HYPERCOAGULABLE STATE IN CANCER-PATIENTS - EVIDENCE FOR IMPAIRED THROMBIN INHIBITIONS 154
V. Plasmaferesi terapeutica 153
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study 153
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia 152
Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells 152
Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin? 151
Molecular biomarkers of thrombosis in myeloproliferative neoplasms 148
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 146
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 146
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study 146
RECOMBINANT VERSUS HIGH-SENSITIVITY CONVENTIONAL THROMBOPLASTIN - A RANDOMIZED CLINICAL-STUDY IN PATIENTS ON ORAL ANTICOAGULATION 145
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 145
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia 144
Procoagulant mechanisms in tumour cells 143
Association of plasma Protein C and CCL18 levels with neurodegenerative measures in Multiple Sclerosis patients 143
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors 142
Unbalanced plasma control of TxA2 and PGI2 synthesis in Vitamin E deficient rats 142
The mechanisms of cancer-associated thrombosis 140
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 140
Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia 139
The effect of Vitamin E or selenium on the oxidant-antioxidant balance in rats 139
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH 139
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 136
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: Results of the prospective collaborative EPICA study 136
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 136
Molecular basis for the relationship between thrombosis and cancer 135
Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps 135
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial 133
The Italian START-Register on anticoagulation with focus on atrial fibrillation 133
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER) 130
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis 130
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 130
Cancer and venous thromboembolism 129
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation 129
Venous thromboembolism in the hematologic malignancies 129
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 129
Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates 128
Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment 128
INEFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH LOW-RISK THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC-UREMIC SYNDROME 128
Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH 126
External validation of the DASH prediction rule: a retrospective cohort study 126
Hemostatic biomarkers in cancer progression 125
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 125
Proceedings of the Fifth International Conference on Thrombosis and Hemostasis Issues in Cancer, held in Stresa - Italy, April 23-25, 2010. Preface. 125
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study 124
Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with Essential Thrombocythemia 124
La coagulopatia indotta da trauma 124
Type and dose of heparin in Covid-19: Reply 124
Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates 124
Risk of Venous Thromboembolism in Surgical Elderly Patients. 123
Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: The HYPERCAN study 122
Microparticles in tumor progression 121
Pharmacological inhibition of thromboxane-synthetase and platelet aggregation: Modulatory role of cyclooxygenase products. 121
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia 121
Thrombosis in myeloproliferative neoplasms 119
Soluble stroma-related biomarkers of pancreatic cancer 119
Edoxaban for the treatment of cancer-associated venous thromboembolism 119
Totale 16.162
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.136
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.136
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021481 0 0 0 0 0 0 0 0 0 162 189 130
2021/20221.563 160 169 178 95 64 76 93 102 69 98 110 349
2022/20232.027 370 568 182 133 95 404 7 90 95 17 41 25
2023/20241.469 26 52 20 18 227 403 259 44 243 20 5 152
2024/20254.320 303 731 200 166 354 74 289 96 414 610 329 754
2025/20267.822 655 606 828 948 924 524 1.317 586 772 662 0 0
Totale 21.716